| HOME >> BIOLOGY >> TECHNOLOGY |
On the basis that blood PSA level alone is not a clear enough indicator of the presence of prostate cancer, this study focused on the evaluation of microscopic structural changes in urine. As an assay, it is believed that this more sensitive test may be able to determine not only the presence of prostate cancer, but its level or aggressiveness, too. "Improvements to prostate cancer staging would be extremely valuable, as well," Dr. Samadi added. "Too often, prostate cancer patients believe they have plenty of time. In reality, prostate cancer can progress very quickly, without notice. Robotic prostatectomy surgery erases the unknown; more accurate staging could help patients reach the decision for life-saving radical prostatectomy surgery sooner."
Researchers conducted the urine-based test on 222 men across three hospitals. The results showed a 100 percent sensitivity, meaning no false negatives; an 80 percent specificity was found, a drastic reduction in false positives from the current PSA test. Further clinical research will be conducted and the test should be available within a year. The test is made by AnalizaDX, Inc., a Cleveland-based biotech company, who will initially conduct the testing of submitted samples at their facilities. "I do hope continued research shows the same level of success with the PSA/SIA assay. Early prostate cancer tests are our best defense," said Dr. Samadi, "I look forward to our ability to deliver increased screening accuracy to our patients."
More can be seen from prostate cancer expert, Dr. David Samadi
'/>"/>
| SOURCE RoboticOncology.com Copyright©2010 PR Newswire. All rights reserved |